
News|Articles|October 5, 2026
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
Author(s)Sheryl Stevenson
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Advertisement
Advertisement
The Nobel Assembly at Karolinska Institutet announced that the 2026 Nobel Prize in Physiology or Medicine will be shared equally among Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute and Stanford University; Peter Hegemann, PhD, of Humboldt University of Berlin; and Georg Nagel, PhD, of the University of Würzburg, “for their discoveries concerning light-gated ion channels and optogenetics.”¹ The prize carries 12 million Swedish kronor—approximately US $1.2 million at current exchange rates—to be split equally among the three laureates.¹
Related to this article

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.
Advertisement
Advertisement

